According to Lannett, the company has signed an agreement with Chinese inhaled drug developer Respirent for exclusive rights to distribute Respirent’s generic version of GSK’s Flovent Diskus fluticasone propionate DPI, which is in early development.
In October 2019, Lannett announced a US distribution deal with Respivent for that company’s generic version of GSK’s Advair Diskus fluticasone propionate/salmeterol xinofoate DPI. That agreement has now been expanded from 10 years to 12 years.
Lannett CEO Tim Crew said, “Expanding our relationship with Respirent for a second powder inhaler product for asthma speaks to the mutual respect we have for each other’s expertise. Generic Flovent Diskus is a large market opportunity product that complements our increasingly important portfolio of inhalation medications. Extending the distribution period for generic Advair Diskus reflects our growing optimism for the product. We remain on track to submit late this calendar year an Abbreviated New Drug Application (ANDA) for this product.”
Read the Lannett press release.
